Clinical Trial Update: A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating bevacizumab in combination with neoadjuvant regimens for HER2-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED